Retrospective, single center evaluation of perineal prostate biopsy omitting antibiotic prophylaxis and omitting periinterventional screening for bacteriuria

Retrospective, single center evaluation of perineal prostate biopsy omitting antibiotic prophylaxis and omitting periinterventional screening for bacteriuria | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Retrospective, single center evaluation of perineal prostate biopsy omitting antibiotic prophylaxis and omitting periinterventional screening for bacteriuria Francois Leboutte, Tim Schykowski, Jeroen van de Plas, Oscar Lemmer, and 1 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4875283/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 19 Jun, 2025 Read the published version in World Journal of Urology → Version 1 posted 10 You are reading this latest preprint version Abstract Purpose The pursuit of effective and safe early detection methods for prostate cancer has led to advancements in non-invasive tools, yet the annual performance of one million prostate biopsies in the EU underscores the challenges. The transperineal approach, recommended by the EAU, offers reduced infectious complications compared to transrectal biopsies. The role of antibiotic prophylaxis in transperineal biopsies remains ambiguous, necessitating investigation due to concerns about antibiotic resistance and the impact on public health. Methods This retrospective study analyzed 636 patients who underwent transperineal prostate biopsies between January 2019 and August 2020. The primary endpoint was postinterventional infectious complications, with secondary endpoints including the general complication rate and associated risk factors. Results Among the cohort (median age 68), 12 complications were recorded, yielding a 1.9% complication rate. Infectious complications requiring hospitalization and antibiotic treatment occurred in 1.1% of cases. No identified risk factors were associated with infectious complications or post-interventional bleeding. Complications included gross hematuria, urinary retention requiring catheterization, and one case necessitating intensive care. Notably, the cohort did not systematically screen for bacteriuria, and patients with high risk for complications were not excluded. The complication rate appeared lower than reported for transrectal biopsies with antibiotic prophylaxis. Conclusion This study supports the safety of omitting antibiotic prophylaxis in transperineal prostate biopsies, showcasing a minimal infectious complication rate. The findings contribute to the ongoing discourse on antibiotic stewardship, emphasizing the need for judicious use to mitigate resistance. Prostatic Neoplasms [MeSH] Image-Guided Biopsy [MeSH] Transperineal Transrectal Fusion biopsy Intraoperative complications [MeSH] Figures Figure 1 1. Introduction The field of early prostate cancer detection has undergone substantial investigation to avoid unnecessary prostate biopsies, obtain accurate histopathological results and minimize morbidity. However, despite advances in non-invasive tools such as mpMRI, PSMA PET scan, risk calculators and ultrasound to determine the risk of prostate cancer, it is estimated that one million prostate biopsies are performed yearly in the EU[ 10 ]. Because of less infectious complications in the transperineal approach, it is considered the best practice according to the EAU guideline [ 10 ] s. While in transrectal biopsies, a peri interventional antibiotic prophylaxis seemed necessary due to contamination passing the unsterile digestive tube, the role of antibiotic prophylaxis in perineal biopsies remains unclear. Its effect has been assessed over the last years in many trials [ 5 , 9 , 11 – 14 ]. A prospective non-inferiority trial by Jazewicz et al. could meet its primary endpoint of non-inferiority concerning infectious complications while omitting antibiotic prophylaxis, using a non-inferiority threshold of 4%.[ 8 ] Two systematic reviews from 2022 could not show a significant difference in infectious complications using or not using peri-interventional antibiotics [ 1 , 4 ]. The unreflective use of antibiotics and the growing cases of resistant organisms has become a significant public health issue. Hulscher et al. showed that indication of 20–50% of all antibiotic therapy was inappropriate[ 7 ]. Correct use of antibiotics is crucial for allowing further effective control of bacterial infection. If omitting antibiotic prophylaxis in a widely used procedure such as prostate biopsy is safe, its impact on public health could be of enormous importance[ 2 , 3 ]. We analyzed the safety of omitting antibiotic prophylaxis in transperineal prostate biopsy without periinterventional screening for bacteriuria retrospectively. The primary endpoint is rate of postinterventional infectious complications. The secondary endpoint is general complication rate and risk factors. 2. Materials and Methods 2.1. Population We retrospectively analyzed 650 consecutive patients who received transperineal prostate biopsies in our urology clinic between January 2019 and August 2020. Patients were eligible if they met the inclusion criteria, which included an indication for prostate biopsy due to suspicion of prostate cancer (pathological PSA value/dynamics, pathological DRE, or pathological MRI) and documented clinical data. Of the 650 patients, 636 met the inclusion criteria for perineal prostate biopsy with complete data (Fig. 1 ). 2.2. Biopsy procedure Transperineal prostate biopsies were performed as outpatient procedures. Before completing the procedure, a short anamnesis was obtained, including operations of the genitourinary tract, indwelling catheter, family history, and existing diseases. A biopsy was not performed if the patient was under anticoagulant medications, except for platelet aggregation inhibitors such as aspirin. After excluding contraindications for prostate biopsy, general consent was obtained, and no blood or urine samples were taken before the intervention. The procedure was performed in lithotomy. The scrotum and penis were taped suprapubic (unsterile Leukoplast – Hypafix 15 cm x 20 m, Beiersdorf AG, Hamburg, Germany). The perineum was shaved when necessary, and gross dirt particles were removed. Antiseptic disinfection was completed with 7.5% Povidone-Iodine solution (Braunol 7.5% Povidon Iod, Braun, Germany). Two dedicated urologists performed the biopsies. Local anesthesia of the skin and periprostatic blockade were performed with a 20G needle (Sterican 20 G 70 mm, Braun, Germany) and 20 ml of Mepivicain 10mg/ml (Mecain, Eugia Pharma PUREN, Malta). Periprostatic block was achieved by finger guidance with the injection of mepivicain below the prostatic apex, bilaterally in the levator ani, and along the needle’s path. 5 to 10 minutes were given for the optimal effect of local anesthesia. Biopsies were performed with a disposable template grid (Template Grid 17/18GA, Civco, Iowa, United States of America). A 24 cm long 18-gauge needle with a hand fire system (CORAZOR, UROMED, Germany) was used for sample collection. Systematic biopsies were performed under local anesthesia (periprostatic nerve block). In MRI Fusion biopsy procedures, we accompanied local anesthesia with sedation (midazolam and ketamine) to minimize the risk of movements during the procedure. UroNav Philips Invivo (Amsterdam, Netherlands) with a template grid was utilized for fusion biopsy combined with the BK 3000, BK Medical (Nærum, Denmark) rectal ultrasound. Systematic biopsies were performed with five cores per half gland. MRI fusion biopsies complemented systematic biopsies with 3 to 4 biopsies per lesion, depending on lesion size and counts. After checking for gross hematuria and the ability to void, the patient was dismissed. 2.3. Outcome variables We chose the following categorical outcome variables: previous biopsy, under active surveillance, previous prostatitis, diabetes mellitus, diabetes mellitus medication, obesity (cut-off body mass index > 35), immunosuppression, anticoagulant therapy (aspirin clopidogrel, phenprocoumon, or a direct oral anticoagulant), indwelling catheter, previous surgery, DRE, performing urologist, type of anesthesia, ISUP grade group, type of complication. In addition, we chose the following continuous outcome variables: age (years), prostate volume (cc), number of MRI lesions, number of cores, and the number of positive cores. 2.4. Statisticsl methods Statistical analyses were conducted using R (Version 4.0.5 for Windows). Non-parametric statistics were applied. Data were presented as raw values and percentages and medians with lower (Q1) and upper quartiles (Q3). We checked for risk factors using multivariate logistic regression. The threshold for a statistically significant difference was p < 0.05. 2.5. Data source Data were collected between January 2022 and December 2022. We retrospectively obtained data from medical charts (i.e., categorical, and continuous outcome variables). 2.6. Bias We encountered two types of bias: Selection bias – the retrospective nature of the trial with 650 patients and less than 2% complications may be insufficient to provide a correct insight into the prevalence of infectious complications. A larger cohort may be necessary when analyzing complications and their risk factors with low incidence. Follow-up bias: follow-up data were collected by chart review from charts of our clinic. No reported outpatient complication treatment (i.e., prescription of antibiotics in the postinterventional course) by another physician may have occurred. Higher-grade complications such as gross macrohematuria with the necessity of bladder irrigation and inpatient treatment with i.v. antibiotics should not have been missed, as our clinic is the only tertiary center in about a 75 km radius and all patients with complications are usually referred to our hospital. 3. Results Overall, 636 patients (median age 68 (62,73) years) with prostate cancer suspicion were included in this study. Demographics and biopsy results are highlighted in Tables 1, 2, and 3. Table 1 Patient demographics and biopsy results Age (years) Missing 68 [62, 73] 0 PSA (ng/ml) Missing 8.5 [6, 13.7] 9 (1.4%) Prostate Volume (ccm) 52.0 [39, 72.3] Indwelling catheter Missing 8 (1.3%) No 598 (94.0%) Yes Missing 32 (5.0%) 6 (0.9%) Active Surveillance No 601 (94.5%) Yes Missing 29 (4.6%) 6 (0.9%) Biopsy technique MRI Fusion biopies 378 (59.4%) Random biopsies 255 (40.1%) Missing 3 (0.5%) Total number of cores 13 [10, 16] Prostate Cancer No Pca 267 (42%) ISUP 1 77 (12.1%) ISUP 2 90 (14.2%) ISUP 3 64 (10.1%) ISUP 4 73 (11.5%) ISUP 5 Missing 59 (9.3%) 6 (0.9%) Results are shown as median, lower and upper quartiles. Table 2 Prostate Cancer detection in Random biopsies n/N (%) ISUP score 0 127/255 49.8% 1 18/255 7.1% 2 16/255 6.3% 3 16/255 6.3% 4 33/255 12.9% 5 42/255 16.5% Missing 3/255 1.2% ISUP grade group - International Society of Urological Pathology Table 3 Prostate Cancer detection in MRI Fusion biopsies n/N (%) ISUP score 0 140/378 37% 1 59/378 15.6% 2 74/378 19.6% 3 48/378 12.7% 4 40/378 10.6% 5 17/378 4.5% Missing 0/378 0% ISUP grade group - International Society of Urological Pathology In total, we recorded 12 complications, representing a complication rate of 1.9%. Details of Clavien Dindo grade are described in table 4. We found 1.1% (7/636) infectious complications needing antibiotic treatment (see table 5). One patient required treatment in the intensive care unit. Furthermore, four patients reported gross hematuria with bladder irrigation. And one patient needed catheterization due to urinary retention. The 11 patients who have been excluded from data analysis; no complications could have been identified in chart review. Table 4 All complications n/N (%) Complications in total 12/636 1.90% Clavien Dindo Grade 1 0/636 Grade 2 11/636 1.70% Grade 3 0/636 Grade 4 1/636 0.16% Grade 5 0/636 Table 5 Infectious complications n/N (%) Infectious complications 7/636 1.10% Type of infectious complication Prostatitis 3/636 0.50% Epididymitis 1/636 0.16% Infection requiring hospitalization 2/636 0.30% Urosepsis wit ICU 1/636 0.16% We could not determine any risk factors for infectious complications (age p=0.44, diabetes mellitus p=0.23, indwelling catheter p=0.26, number of cores p =0.6, prostate volume p=0.44), post-interventional bleeding (age p=0.75, under anticoagulant agent p=0.5, number of cores p =0.14, prostate volume p=0.10). Table 6 highlights those patients who suffered from an infectious complication and their clinical details (see table 6). 4. Discussion 4.1. Main Findings Our study reported complications after transperineal prostate biopsy omitting peri-interventional antibiotic prophylaxis and not screening for bacteriuria in a single-center retrospective cohort of 632 patients. Most trials do not mention if patients were excluded from the trial after performing urine analysis showing bacteriuria. In our cohort, patients were not systematically screened for underlying UTI/bacteriuria. As the transperineal route does not systematically injure the mucosa, there is no rationale for systematic bacteriuria screening. If there is clinical evidence of symptomatic UTI, we perform further diagnostics including urine microscopy and cultures, and biopsy is postponed after treatment of the underlying UTI. Furthermore, we did not exclude patients with a "high risk for infectious complication after prostate biopsy." In our cohort, the only contraindication for prostate biopsy would have been a clinically evident underlying UTI. If the patient complained of pollacisuria with alguria and/or fever, we would collect a urine sample, and if deemed necessary, start an antibiotic therapy. However, in our cohort of 650 patients, we did not postpone any prostate biopsy due to UTI. High risk for infectious complication after prostate biopsy is not clearly defined. In the NORAPP trial, the following criteria were defined for high risk: indwelling urinary catheter, immunodeficiencies, high risk of infective endocarditis, or a history of thromboembolic disease. We reported a low complication rate of 1.9% with 11 Clavien Dindo grade (CD) 2 complications and one CD 4 complication. The most common complications were infectious complications. The rate of infectious complications for the transperineal prostate biopsy without antibiotic prophylaxis in our cohort (ca. 1. %) seemed to be lower than for transrectal prostate biopsy with antibiotic prophylaxis (approx. 5%)[ 6 ]. The total number of low-grade complications may have been a little higher, as not all patients may have been referred back to our clinic and remember retrospectively if they have been prescribed an oral medication (i.e. antibiotics) by a private consultant. Higher-grade complications (Clavien Dindo Grade > 2) were likely not missed, as our tertiary medical care center comprises the only urological unit in a radius of about 75 km. Risk factors for infectious or bleeding complications did not meet statistical significance. This may have been due to our cohort's relatively low number of complications. 4.2. Findings of biopsy results Histologically confirmed prostate cancer was more often found in fusion biopsy than in systematic biopsies (Tables 2 and 3). High-grade prostate cancer (ISUP > 3) was more frequently found in the group of systematic biopsies. An explanation could be that we did not perform upfront MRIs when there was a high risk for prostate cancer, such as PSA > 20 ng/ml or suspicious DRE. Therefore, systematic biopsies had a negative selection bias for ISUP grade compared to the group of MRI fusion biopsies. 4.3. Limitations The main limitation of this study is that follow-up data has been collected with a retrospective chart review. Also, as mentioned, our tertiary referral clinic is the only hospital with a urology department in a radius of around 75 km, but other urologist/physician may have treated minor adverse events such as UTI without fever or a simple postoperative prostatitis two staged and some patients might not have recalled correctly afterwards. 5. Conclusions Our report confirmed existing data showing a low number of infectious complications when using the transperineal route for prostate biopsies and omitting antibiotic prophylaxis. We did not assess systematically for underlying bacteriuria and still had a very low complication rate. Omitting antibiotic prophylaxis and omitting screening for bacteriuria seems to be safe in transperineal prostate biopsies. Declarations Author Contributions: Conceptualization, methods, and investigation, F.L.,T.S.; Data mining, investigation and draft preparation was incorporated in academic formulation for a medical doctor thesis at the University Medical Center of the Johannes Gutenberg-University Mainz; formal analysis, F.L.; writing—original draft preparation, F.L.; writing—review and editing, F.L.,T.S., A.N.; visualization, F.L..; conceptualization and supervision, A.N.. All authors have read and agreed to the published version of the manuscript. Funding: This research received no funding. Institutional Review Board Statement: This retrospective cohort study was conducted in accordance with the Declaration of Helsinki, and approved by our local ethics committee (Ethics Committee of the Mainz Medical Association (2022-16318)). Further, this study is reported in accordance with the STROBE statement guideline for cohort studies. Informed Consent Statement: Patient consent was waived due to the retrospective nature of this study. Further, given the provided information, patients cannot be identified (including by the patients themselves). Data Availability Statement: De-identified data is available upon request from the authors. Acknowledgments: None. Conflicts of Interest: All authors declare no conflict of interest. Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of World Journal of Urology and/or the editor(s). World Journal of Urology and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. References Basourakos SP, Alshak MN, Lewicki PJ, Cheng E, Tzeng M, DeRosa AP, Allaway MJ, Ross AE, Schaeffer EM, Patel HD, Hu JC, Gorin MA (2022) Role of Prophylactic Antibiotics in Transperineal Prostate Biopsy: A Systematic Review and Meta-analysis. Eur Urol Open Sci 37:53–63. doi: 10.1016/j.euros.2022.01.001 Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M (2014) A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis 14:1–25. doi: 10.1186/1471-2334-14-13 Bootsma AMJ, Laguna Pes MP, Geerlings SE, Goossens A (2008) Antibiotic Prophylaxis in Urologic Procedures: A Systematic Review. Eur Urol 54:1270–1286. doi: 10.1016/j.eururo.2008.03.033 Castellani D, Pirola GM, Law YXT, Gubbiotti M, Giulioni C, Scarcella S, Wroclawski ML, Chan E, Chiu PKF, Teoh JYC, Gauhar V, Rubilotta E (2022) Infection Rate after Transperineal Prostate Biopsy with and without Prophylactic Antibiotics: Results from a Systematic Review and Meta-Analysis of Comparative Studies. Journal of Urology 207:25–34 Ding X fei, Luan Y, Lu S ming, Zhou G chen, Huang T bao, Zhu L yong, Guo C hao (2021) Risk factors for infection complications after transrectal ultrasound-guided transperineal prostate biopsy. World J Urol 39:2463–2467. doi: 10.1007/s00345-020-03454-y Guo LH, Wu R, Xu HX, Xu JM, Wu J, Wang S, Bo XW, Liu BJ (2015) Comparison between Ultrasound Guided Transperineal and Transrectal Prostate Biopsy: A Prospective, Randomized, and Controlled Trial. Sci Rep 5:1–10. doi: 10.1038/srep16089 Hulscher ME, Grol RP, van der Meer JW (2010) Antibiotic prescribing in hospitals: a social and behavioural scientific approach. Lancet Infect Dis 10:167–175. doi: 10.1016/S1473-3099(10)70027-X Jacewicz M, Günzel K, Rud E, Sandbæk G, Magheli A, Busch J, Hinz S, Baco E (2022) Antibiotic prophylaxis versus no antibiotic prophylaxis in transperineal prostate biopsies (NORAPP): a randomised, open-label, non-inferiority trial. Lancet Infect Dis 22:1465–1471. doi: 10.1016/S1473-3099(22)00373-5 Kohl T, Sigle A, Kuru T, Salem J, Rolfs H, Kowalke T, Suarez-Ibarrola R, Michaelis J, Binder N, Jilg CA, Miernik A, Grabbert MT, Schultze-Seemann W, Gratzke C, Porres D (2021) Comprehensive analysis of complications after transperineal prostate biopsy without antibiotic prophylaxis: results of a multicenter trial with 30 days’ follow-up. Prostate Cancer Prostatic Dis 1–5. doi: 10.1038/s41391-021-00423-3 Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, van der Kwast TH, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, van der Poel HG, Rouvière O, Schoots IG, Tilki D, Wiegel T, Willemse PPM, Cornford P (2021) EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 79:243–262. doi: 10.1016/j.eururo.2020.09.042 Pepdjonovic L, Tan GH, Huang S, Mann S, Frydenberg M, Moon D, Hanegbi U, Landau A, Snow R, Grummet J (2017) Zero hospital admissions for infection after 577 transperineal prostate biopsies using single-dose cephazolin prophylaxis. World J Urol 35:1199–1203. doi: 10.1007/s00345-016-1985-1 Sigle A, Suarez-Ibarrola R, Pudimat M, Michaelis J, Jilg CA, Miernik A, Grabbert MT, Schultze-Seemann W, Gratzke C, Schlager D (2021) Safety and side effects of transperineal prostate biopsy without antibiotic prophylaxis. Urologic Oncology: Seminars and Original Investigations 39:782.e1-782.e5. doi: 10.1016/j.urolonc.2021.02.016 Sigle A, Suarez-Ibarrola R, Pudimat M, Michaelis J, Jilg CA, Miernik A, Grabbert MT, Schultze-Seemann W, Gratzke C, Schlager D, Pepdjonovic L, Tan GH, Huang S, Mann S, Frydenberg M, Moon D, Hanegbi U, Landau A, Snow R, Grummet J, Baba K, Sekine Y, Miyazawa Y, Syuto T, Nomura M, Koike H, Matsui H, Shibata Y, Ito K, Suzuki K (2017) Safety and side effects of transperineal prostate biopsy without antibiotic prophylaxis. World J Urol 39:1199–1203. doi: 10.1007/s00345-016-1985-1 Xiang J, Yan H, Li J, Wang X, Chen H, Zheng X (2019) Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: A systematic review and meta-analysis. World J Surg Oncol 17:1–11. doi: 10.1186/s12957-019-1573-0 Additional Declarations No competing interests reported. Cite Share Download PDF Status: Published Journal Publication published 19 Jun, 2025 Read the published version in World Journal of Urology → Version 1 posted Editorial decision: Revision requested 19 Dec, 2024 Reviews received at journal 18 Dec, 2024 Reviewers agreed at journal 04 Dec, 2024 Reviewers agreed at journal 02 Dec, 2024 Reviews received at journal 12 Sep, 2024 Reviewers agreed at journal 30 Aug, 2024 Reviewers invited by journal 27 Aug, 2024 Editor assigned by journal 21 Aug, 2024 Submission checks completed at journal 20 Aug, 2024 First submitted to journal 07 Aug, 2024 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4875283","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":352887939,"identity":"6e358420-6b74-4f17-98ae-fdd14de5d9b7","order_by":0,"name":"Francois Leboutte","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA9UlEQVRIiWNgGAWjYBAC9gbmBmYIk/kYM0KcDbcWngOMYC0SPAxsacwMCaRp4TEjUgsDY+PjgorDdfbsPd8eF/6ozTe43XvwAUOZDT4tzcYzzhyW4OE5u914RsJxyw13ziUbMJxLw6nFnoGxTZq3DahFInebNE/CMQODGzlmEoxth/HZ0v4brEX+zTOYFvMfjG3/8WlpY4bYwsMG1FIDtgUoeAC3FmbGZukZZ9Ile86kmRvPSDtgIAn0i0TCuWTcWtibD34uqLDmZ28//OxxgU2dAR8wxD58KLPDqYWBGZV7GBxFiPghAtRBtIyCUTAKRsEoQAIA83NP8jnK9yQAAAAASUVORK5CYII=","orcid":"","institution":"Krankenhaus der Barmherzige Brüdern Trier, Medizincampus Trier der Universitätsmedizin Mainz","correspondingAuthor":true,"prefix":"","firstName":"Francois","middleName":"","lastName":"Leboutte","suffix":""},{"id":352887940,"identity":"8270b923-cd0b-4eaf-bb47-8cf7c6f31d24","order_by":1,"name":"Tim Schykowski","email":"","orcid":"","institution":"Helios Dr. Horst Schmidt Kliniken Wiesbaden","correspondingAuthor":false,"prefix":"","firstName":"Tim","middleName":"","lastName":"Schykowski","suffix":""},{"id":352887941,"identity":"dd8baad3-c105-453c-84f6-fc5226da91d0","order_by":2,"name":"Jeroen van de Plas","email":"","orcid":"","institution":"Krankenhaus der Barmherzige Brüdern Trier, Medizincampus Trier der Universitätsmedizin Mainz","correspondingAuthor":false,"prefix":"","firstName":"Jeroen","middleName":"van","lastName":"de Plas","suffix":""},{"id":352887942,"identity":"b01b3dec-5bda-4e65-b70d-95e6e66ec168","order_by":3,"name":"Oscar Lemmer","email":"","orcid":"","institution":"Krankenhaus der Barmherzige Brüdern Trier, Medizincampus Trier der Universitätsmedizin Mainz","correspondingAuthor":false,"prefix":"","firstName":"Oscar","middleName":"","lastName":"Lemmer","suffix":""},{"id":352887943,"identity":"849b11b7-addf-45b1-8d14-3a52fa0f0000","order_by":4,"name":"Andreas Neisius","email":"","orcid":"","institution":"Krankenhaus der Barmherzige Brüdern Trier, Medizincampus Trier der Universitätsmedizin Mainz","correspondingAuthor":false,"prefix":"","firstName":"Andreas","middleName":"","lastName":"Neisius","suffix":""}],"badges":[],"createdAt":"2024-08-07 13:56:56","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4875283/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4875283/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1007/s00345-025-05672-8","type":"published","date":"2025-06-19T15:57:09+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":66656035,"identity":"e41a9aa1-6185-4415-9415-ea6a833984a2","added_by":"auto","created_at":"2024-10-15 08:18:39","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":31077,"visible":true,"origin":"","legend":"\u003cp\u003eStudy flow diagram\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-4875283/v1/21f4784f92c2d1d0434211da.png"},{"id":85231455,"identity":"70375ece-5e98-4cc4-8f58-2669c80c244b","added_by":"auto","created_at":"2025-06-23 16:08:32","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":687020,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4875283/v1/c7e783e3-ba03-4bc5-b522-06ea154c4a14.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Retrospective, single center evaluation of perineal prostate biopsy omitting antibiotic prophylaxis and omitting periinterventional screening for bacteriuria","fulltext":[{"header":"1. Introduction","content":"\u003cp\u003e\u003cdiv class=\"BlockQuote\"\u003e\u003cp\u003eThe field of early prostate cancer detection has undergone substantial investigation to avoid unnecessary prostate biopsies, obtain accurate histopathological results and minimize morbidity. However, despite advances in non-invasive tools such as mpMRI, PSMA PET scan, risk calculators and ultrasound to determine the risk of prostate cancer, it is estimated that one million prostate biopsies are performed yearly in the EU[\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eBecause of less infectious complications in the transperineal approach, it is considered the best practice according to the EAU guideline [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e] s. While in transrectal biopsies, a peri interventional antibiotic prophylaxis seemed necessary due to contamination passing the unsterile digestive tube, the role of antibiotic prophylaxis in perineal biopsies remains unclear. Its effect has been assessed over the last years in many trials [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan additionalcitationids=\"CR12 CR13\" citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. A prospective non-inferiority trial by Jazewicz et al. could meet its primary endpoint of non-inferiority concerning infectious complications while omitting antibiotic prophylaxis, using a non-inferiority threshold of 4%.[\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e] Two systematic reviews from 2022 could not show a significant difference in infectious complications using or not using peri-interventional antibiotics [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eThe unreflective use of antibiotics and the growing cases of resistant organisms has become a significant public health issue. Hulscher et al. showed that indication of 20\u0026ndash;50% of all antibiotic therapy was inappropriate[\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. Correct use of antibiotics is crucial for allowing further effective control of bacterial infection. If omitting antibiotic prophylaxis in a widely used procedure such as prostate biopsy is safe, its impact on public health could be of enormous importance[\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eWe analyzed the safety of omitting antibiotic prophylaxis in transperineal prostate biopsy without periinterventional screening for bacteriuria retrospectively. The primary endpoint is rate of postinterventional infectious complications. The secondary endpoint is general complication rate and risk factors.\u003c/p\u003e\u003c/div\u003e\u003c/p\u003e"},{"header":"2. Materials and Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003e2.1. Population\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eWe retrospectively analyzed 650 consecutive patients who received transperineal prostate biopsies in our urology clinic between January 2019 and August 2020. Patients were eligible if they met the inclusion criteria, which included an indication for prostate biopsy due to suspicion of prostate cancer (pathological PSA value/dynamics, pathological DRE, or pathological MRI) and documented clinical data. Of the 650 patients, 636 met the inclusion criteria for perineal prostate biopsy with complete data (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003e2.2. Biopsy procedure\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eTransperineal prostate biopsies were performed as outpatient procedures. Before completing the procedure, a short anamnesis was obtained, including operations of the genitourinary tract, indwelling catheter, family history, and existing diseases. A biopsy was not performed if the patient was under anticoagulant medications, except for platelet aggregation inhibitors such as aspirin. After excluding contraindications for prostate biopsy, general consent was obtained, and no blood or urine samples were taken before the intervention.\u003c/p\u003e \u003cp\u003eThe procedure was performed in lithotomy. The scrotum and penis were taped suprapubic (unsterile Leukoplast \u0026ndash; Hypafix 15 cm x 20 m, Beiersdorf AG, Hamburg, Germany). The perineum was shaved when necessary, and gross dirt particles were removed. Antiseptic disinfection was completed with 7.5% Povidone-Iodine solution (Braunol 7.5% Povidon Iod, Braun, Germany). Two dedicated urologists performed the biopsies. Local anesthesia of the skin and periprostatic blockade were performed with a 20G needle (Sterican 20 G 70 mm, Braun, Germany) and 20 ml of Mepivicain 10mg/ml (Mecain, Eugia Pharma PUREN, Malta). Periprostatic block was achieved by finger guidance with the injection of mepivicain below the prostatic apex, bilaterally in the levator ani, and along the needle\u0026rsquo;s path. 5 to 10 minutes were given for the optimal effect of local anesthesia. Biopsies were performed with a disposable template grid (Template Grid 17/18GA, Civco, Iowa, United States of America). A 24 cm long 18-gauge needle with a hand fire system (CORAZOR, UROMED, Germany) was used for sample collection.\u003c/p\u003e \u003cp\u003eSystematic biopsies were performed under local anesthesia (periprostatic nerve block). In MRI Fusion biopsy procedures, we accompanied local anesthesia with sedation (midazolam and ketamine) to minimize the risk of movements during the procedure.\u003c/p\u003e \u003cp\u003eUroNav Philips Invivo (Amsterdam, Netherlands) with a template grid was utilized for fusion biopsy combined with the BK 3000, BK Medical (N\u0026aelig;rum, Denmark) rectal ultrasound. Systematic biopsies were performed with five cores per half gland. MRI fusion biopsies complemented systematic biopsies with 3 to 4 biopsies per lesion, depending on lesion size and counts.\u003c/p\u003e \u003cp\u003eAfter checking for gross hematuria and the ability to void, the patient was dismissed.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003e2.3. Outcome variables\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eWe chose the following categorical outcome variables: previous biopsy, under active surveillance, previous prostatitis, diabetes mellitus, diabetes mellitus medication, obesity (cut-off body mass index\u0026thinsp;\u0026gt;\u0026thinsp;35), immunosuppression, anticoagulant therapy (aspirin clopidogrel, phenprocoumon, or a direct oral anticoagulant), indwelling catheter, previous surgery, DRE, performing urologist, type of anesthesia, ISUP grade group, type of complication. In addition, we chose the following continuous outcome variables: age (years), prostate volume (cc), number of MRI lesions, number of cores, and the number of positive cores.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003e2.4. Statisticsl methods\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eStatistical analyses were conducted using R (Version 4.0.5 for Windows). Non-parametric statistics were applied. Data were presented as raw values and percentages and medians with lower (Q1) and upper quartiles (Q3). We checked for risk factors using multivariate logistic regression. The threshold for a statistically significant difference was p\u0026thinsp;\u0026lt;\u0026thinsp;0.05.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003e2.5. Data source\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eData were collected between January 2022 and December 2022. We retrospectively obtained data from medical charts (i.e., categorical, and continuous outcome variables).\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003e2.6. Bias\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eWe encountered two types of bias:\u003c/p\u003e \u003cul\u003e\u003cli\u003e\u003cp\u003eSelection bias \u0026ndash; the retrospective nature of the trial with 650 patients and less than 2% complications may be insufficient to provide a correct insight into the prevalence of infectious complications. A larger cohort may be necessary when analyzing complications and their risk factors with low incidence.\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eFollow-up bias: follow-up data were collected by chart review from charts of our clinic. No reported outpatient complication treatment (i.e., prescription of antibiotics in the postinterventional course) by another physician may have occurred. Higher-grade complications such as gross macrohematuria with the necessity of bladder irrigation and inpatient treatment with i.v. antibiotics should not have been missed, as our clinic is the only tertiary center in about a 75 km radius and all patients with complications are usually referred to our hospital.\u003c/p\u003e\u003c/li\u003e\u003c/ul\u003e"},{"header":"3. Results","content":"\u003cp\u003eOverall, 636 patients (median age 68 (62,73) years) with prostate cancer suspicion were included in this study. Demographics and biopsy results are highlighted in Tables 1, 2, and 3.\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"580\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"83.10344827586206%\" colspan=\"5\" valign=\"top\" style=\"width: 45.5939%;\"\u003e\n \u003cp\u003eTable 1 Patient demographics and biopsy results\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"26.03448275862069%\" colspan=\"2\" valign=\"top\" style=\"width: 19.1119%;\"\u003e\n \u003cp\u003eAge (years)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.137931034482758%\" colspan=\"2\" valign=\"top\" style=\"width: 16.9758%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003eMissing\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.103448275862068%\" valign=\"top\" style=\"width: 17.0883%;\"\u003e\n \u003cp\u003e68 [62, 73]\u003c/p\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"26.03448275862069%\" colspan=\"2\" valign=\"top\" style=\"width: 19.1119%;\"\u003e\n \u003cp\u003ePSA (ng/ml)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.137931034482758%\" colspan=\"2\" valign=\"top\" style=\"width: 16.9758%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003eMissing\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.103448275862068%\" valign=\"top\" style=\"width: 17.0883%;\"\u003e\n \u003cp\u003e8.5 [6, 13.7]\u003c/p\u003e\n \u003cp\u003e9 (1.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.172413793103445%\" colspan=\"2\" valign=\"top\" style=\"width: 19.1119%;\"\u003e\n \u003cp\u003eProstate Volume (ccm)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.82758620689655%\" colspan=\"2\" valign=\"top\" style=\"width: 16.9758%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.103448275862068%\" valign=\"top\" style=\"width: 17.0883%;\"\u003e\n \u003cp\u003e52.0 [39, 72.3]\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"26.03448275862069%\" colspan=\"2\" valign=\"top\" style=\"width: 19.1119%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003eIndwelling catheter\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.137931034482758%\" colspan=\"2\" valign=\"top\" style=\"width: 16.9758%;\"\u003e\n \u003cp\u003eMissing\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.103448275862068%\" valign=\"top\" style=\"width: 17.0883%;\"\u003e\n \u003cp\u003e8 (1.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"26.03448275862069%\" colspan=\"2\" valign=\"top\" style=\"width: 19.1119%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.137931034482758%\" colspan=\"2\" valign=\"top\" style=\"width: 16.9758%;\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.103448275862068%\" valign=\"top\" style=\"width: 17.0883%;\"\u003e\n \u003cp\u003e598 (94.0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"26.03448275862069%\" colspan=\"2\" valign=\"top\" style=\"width: 19.1119%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.137931034482758%\" colspan=\"2\" valign=\"top\" style=\"width: 16.9758%;\"\u003e\n \u003cp\u003eYes\u003c/p\u003e\n \u003cp\u003eMissing\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.103448275862068%\" valign=\"top\" style=\"width: 17.0883%;\"\u003e\n \u003cp\u003e32 (5.0%)\u003c/p\u003e\n \u003cp\u003e6 (0.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"26.03448275862069%\" colspan=\"2\" valign=\"top\" style=\"width: 19.1119%;\"\u003e\n \u003cp\u003eActive Surveillance\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.137931034482758%\" colspan=\"2\" valign=\"top\" style=\"width: 16.9758%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.103448275862068%\" valign=\"top\" style=\"width: 17.0883%;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"26.03448275862069%\" colspan=\"2\" valign=\"top\" style=\"width: 19.1119%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.137931034482758%\" colspan=\"2\" valign=\"top\" style=\"width: 16.9758%;\"\u003e\n \u003cp\u003eNo\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.103448275862068%\" valign=\"top\" style=\"width: 17.0883%;\"\u003e\n \u003cp\u003e601 (94.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"26.03448275862069%\" colspan=\"2\" valign=\"top\" style=\"width: 19.1119%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.137931034482758%\" colspan=\"2\" valign=\"top\" style=\"width: 16.9758%;\"\u003e\n \u003cp\u003eYes\u003c/p\u003e\n \u003cp\u003eMissing\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.103448275862068%\" valign=\"top\" style=\"width: 17.0883%;\"\u003e\n \u003cp\u003e29 (4.6%)\u003c/p\u003e\n \u003cp\u003e6 (0.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"26.03448275862069%\" colspan=\"2\" valign=\"top\" style=\"width: 19.1119%;\"\u003e\n \u003cp\u003eBiopsy technique\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.137931034482758%\" colspan=\"2\" valign=\"top\" style=\"width: 16.9758%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.103448275862068%\" valign=\"top\" style=\"width: 17.0883%;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"26.03448275862069%\" colspan=\"2\" valign=\"top\" style=\"width: 19.1119%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.137931034482758%\" colspan=\"2\" valign=\"top\" style=\"width: 16.9758%;\"\u003e\n \u003cp\u003eMRI Fusion biopies\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.103448275862068%\" valign=\"top\" style=\"width: 17.0883%;\"\u003e\n \u003cp\u003e378 (59.4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"26.03448275862069%\" colspan=\"2\" valign=\"top\" style=\"width: 19.1119%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.137931034482758%\" colspan=\"2\" valign=\"top\" style=\"width: 16.9758%;\"\u003e\n \u003cp\u003eRandom biopsies\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.103448275862068%\" valign=\"top\" style=\"width: 17.0883%;\"\u003e\n \u003cp\u003e255 (40.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"26.03448275862069%\" colspan=\"2\" valign=\"top\" style=\"width: 19.1119%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.137931034482758%\" colspan=\"2\" valign=\"top\" style=\"width: 16.9758%;\"\u003e\n \u003cp\u003eMissing\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.103448275862068%\" valign=\"top\" style=\"width: 17.0883%;\"\u003e\n \u003cp\u003e3 (0.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"26.03448275862069%\" colspan=\"2\" valign=\"top\" style=\"width: 19.1119%;\"\u003e\n \u003cp\u003eTotal number of cores\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.137931034482758%\" colspan=\"2\" valign=\"top\" style=\"width: 16.9758%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.103448275862068%\" valign=\"top\" style=\"width: 17.0883%;\"\u003e\n \u003cp\u003e13 [10, 16]\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"26.03448275862069%\" colspan=\"2\" valign=\"top\" style=\"width: 19.1119%;\"\u003e\n \u003cp\u003eProstate Cancer\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.137931034482758%\" colspan=\"2\" valign=\"top\" style=\"width: 16.9758%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.103448275862068%\" valign=\"top\" style=\"width: 17.0883%;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"26.03448275862069%\" colspan=\"2\" valign=\"top\" style=\"width: 19.1119%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.137931034482758%\" colspan=\"2\" valign=\"top\" style=\"width: 16.9758%;\"\u003e\n \u003cp\u003eNo Pca\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.103448275862068%\" valign=\"top\" style=\"width: 17.0883%;\"\u003e\n \u003cp\u003e267 (42%)\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"26.03448275862069%\" colspan=\"2\" valign=\"top\" style=\"width: 19.1119%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.137931034482758%\" colspan=\"2\" valign=\"top\" style=\"width: 16.9758%;\"\u003e\n \u003cp\u003eISUP 1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.103448275862068%\" valign=\"top\" style=\"width: 17.0883%;\"\u003e\n \u003cp\u003e77 (12.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"26.03448275862069%\" colspan=\"2\" valign=\"top\" style=\"width: 19.1119%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.137931034482758%\" colspan=\"2\" valign=\"top\" style=\"width: 16.9758%;\"\u003e\n \u003cp\u003eISUP 2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.103448275862068%\" valign=\"top\" style=\"width: 17.0883%;\"\u003e\n \u003cp\u003e90 (14.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"26.03448275862069%\" colspan=\"2\" valign=\"top\" style=\"width: 19.1119%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.137931034482758%\" colspan=\"2\" valign=\"top\" style=\"width: 16.9758%;\"\u003e\n \u003cp\u003eISUP 3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.103448275862068%\" valign=\"top\" style=\"width: 17.0883%;\"\u003e\n \u003cp\u003e64 (10.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"26.03448275862069%\" colspan=\"2\" valign=\"top\" style=\"width: 19.1119%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.137931034482758%\" colspan=\"2\" valign=\"top\" style=\"width: 16.9758%;\"\u003e\n \u003cp\u003eISUP 4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.103448275862068%\" valign=\"top\" style=\"width: 17.0883%;\"\u003e\n \u003cp\u003e73 (11.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"26.03448275862069%\" colspan=\"2\" valign=\"top\" style=\"width: 19.1119%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.137931034482758%\" colspan=\"2\" valign=\"top\" style=\"width: 16.9758%;\"\u003e\n \u003cp\u003eISUP 5\u003c/p\u003e\n \u003cp\u003eMissing\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.103448275862068%\" valign=\"top\" style=\"width: 17.0883%;\"\u003e\n \u003cp\u003e59 (9.3%)\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e6 (0.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eResults are shown as median, lower and upper quartiles. \u0026nbsp;\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"337\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"89.88095238095238%\" colspan=\"6\" valign=\"bottom\"\u003e\n \u003cp\u003eTable 2 Prostate Cancer detection in Random biopsies\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"5.341246290801187%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"42.433234421364986%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"42.13649851632047%\" colspan=\"2\"\u003e\n \u003cp\u003en/N\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.089020771513352%\"\u003e\n \u003cp\u003e(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"100%\" colspan=\"6\"\u003e\n \u003cp\u003e\u003cstrong\u003eISUP score\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"13.988095238095237%\" colspan=\"2\" valign=\"bottom\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd width=\"30.952380952380953%\"\u003e\n \u003cp\u003e0 \u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"44.94047619047619%\" colspan=\"2\"\u003e\n \u003cp\u003e127/255\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.119047619047619%\"\u003e\n \u003cp\u003e49.8%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"13.988095238095237%\" colspan=\"2\" valign=\"bottom\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd width=\"30.952380952380953%\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"44.94047619047619%\" colspan=\"2\"\u003e\n \u003cp\u003e18/255\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.119047619047619%\"\u003e\n \u003cp\u003e7.1%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"13.988095238095237%\" colspan=\"2\" valign=\"bottom\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"30.952380952380953%\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"44.94047619047619%\" colspan=\"2\"\u003e\n \u003cp\u003e16/255\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.119047619047619%\"\u003e\n \u003cp\u003e6.3%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"13.988095238095237%\" colspan=\"2\" valign=\"bottom\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"30.952380952380953%\"\u003e\n \u003cp\u003e3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"44.94047619047619%\" colspan=\"2\"\u003e\n \u003cp\u003e16/255\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.119047619047619%\"\u003e\n \u003cp\u003e6.3%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"13.988095238095237%\" colspan=\"2\" valign=\"bottom\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"30.952380952380953%\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"44.94047619047619%\" colspan=\"2\"\u003e\n \u003cp\u003e33/255\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.119047619047619%\"\u003e\n \u003cp\u003e12.9%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"13.988095238095237%\" colspan=\"2\" valign=\"bottom\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"30.952380952380953%\"\u003e\n \u003cp\u003e5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"44.94047619047619%\" colspan=\"2\"\u003e\n \u003cp\u003e42/255\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.119047619047619%\"\u003e\n \u003cp\u003e16.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"13.988095238095237%\" colspan=\"2\" valign=\"bottom\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"30.952380952380953%\"\u003e\n \u003cp\u003eMissing\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"44.94047619047619%\" colspan=\"2\"\u003e\n \u003cp\u003e3/255\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.119047619047619%\"\u003e\n \u003cp\u003e1.2%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eISUP grade group - International Society of Urological Pathology\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"337\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"95.25222551928783%\" colspan=\"4\" valign=\"bottom\" style=\"width: 36.7246%;\"\u003e\n \u003cp\u003eTable 3 Prostate Cancer detection in MRI Fusion biopsies\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"42.30769230769231%\" colspan=\"2\" style=\"width: 23.4905%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"47.633136094674555%\" style=\"width: 13.2341%;\"\u003e\n \u003cp\u003en/N\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"4.733727810650888%\" style=\"width: 3.249%;\"\u003e\n \u003cp\u003e(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"100%\" colspan=\"4\" style=\"width: 51.7783%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eISUP score\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"30.86053412462908%\" style=\"width: 8.7676%;\"\u003e\n \u003cp\u003e0 \u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"50.445103857566764%\" colspan=\"2\" style=\"width: 27.957%;\"\u003e\n \u003cp\u003e140/378\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"4.747774480712166%\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e37%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"30.86053412462908%\" style=\"width: 8.7676%;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"50.445103857566764%\" colspan=\"2\" style=\"width: 27.957%;\"\u003e\n \u003cp\u003e59/378\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"4.747774480712166%\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e15.6%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"30.86053412462908%\" style=\"width: 8.7676%;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"50.445103857566764%\" colspan=\"2\" style=\"width: 27.957%;\"\u003e\n \u003cp\u003e74/378\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"4.747774480712166%\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e19.6%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"30.86053412462908%\" style=\"width: 8.7676%;\"\u003e\n \u003cp\u003e3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"50.445103857566764%\" colspan=\"2\" style=\"width: 27.957%;\"\u003e\n \u003cp\u003e48/378\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"4.747774480712166%\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e12.7%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"30.86053412462908%\" style=\"width: 8.7676%;\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"50.445103857566764%\" colspan=\"2\" style=\"width: 27.957%;\"\u003e\n \u003cp\u003e40/378\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"4.747774480712166%\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e10.6%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"30.86053412462908%\" style=\"width: 8.7676%;\"\u003e\n \u003cp\u003e5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"50.445103857566764%\" colspan=\"2\" style=\"width: 27.957%;\"\u003e\n \u003cp\u003e17/378\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"4.747774480712166%\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e4.5%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"30.86053412462908%\" style=\"width: 8.7676%;\"\u003e\n \u003cp\u003eMissing\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"50.445103857566764%\" colspan=\"2\" style=\"width: 27.957%;\"\u003e\n \u003cp\u003e0/378\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"4.747774480712166%\" style=\"width: 18.8586%;\"\u003e\n \u003cp\u003e0%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eISUP grade group - International Society of Urological Pathology\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eIn total, we recorded 12 complications, representing a complication rate of 1.9%. Details of Clavien Dindo grade are described in table 4. We found 1.1% (7/636) infectious complications needing antibiotic treatment (see table 5). One patient required treatment in the intensive care unit. Furthermore, four patients reported gross hematuria with bladder irrigation. And one patient needed catheterization due to urinary retention. The 11 patients who have been excluded from data analysis; no complications could have been identified in chart review.\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"303\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"99.66996699669967%\" colspan=\"5\" valign=\"bottom\" style=\"width: 39.9351%;\"\u003e\n \u003cp\u003eTable 4 All complications\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.584158415841586%\" colspan=\"2\" valign=\"bottom\" style=\"width: 22.9592%;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd width=\"27.062706270627064%\" colspan=\"2\" valign=\"bottom\" style=\"width: 8.4879%;\"\u003e\n \u003cp\u003en/N\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.072607260726073%\" valign=\"bottom\" style=\"width: 8.4879%;\"\u003e\n \u003cp\u003e(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"46.53465346534654%\" colspan=\"2\" valign=\"bottom\" style=\"width: 22.9592%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eComplications in total\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.062706270627064%\" colspan=\"2\" valign=\"bottom\" style=\"width: 8.4879%;\"\u003e\n \u003cp\u003e12/636\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.072607260726073%\" valign=\"bottom\" style=\"width: 8.4879%;\"\u003e\n \u003cp\u003e1.90%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"99.66996699669967%\" colspan=\"5\" valign=\"bottom\" style=\"width: 39.9351%;\"\u003e\n \u003cp\u003eClavien Dindo\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.584158415841586%\" colspan=\"2\" valign=\"bottom\" style=\"width: 26.4378%;\"\u003e\n \u003cp\u003eGrade 1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.062706270627064%\" colspan=\"2\" valign=\"bottom\" style=\"width: 9.0445%;\"\u003e\n \u003cp\u003e0/636\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.072607260726073%\" valign=\"bottom\" style=\"width: 6.4007%;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.584158415841586%\" colspan=\"2\" valign=\"bottom\" style=\"width: 26.4378%;\"\u003e\n \u003cp\u003eGrade 2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.062706270627064%\" colspan=\"2\" valign=\"bottom\" style=\"width: 9.0445%;\"\u003e\n \u003cp\u003e11/636\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.072607260726073%\" valign=\"bottom\" style=\"width: 6.4007%;\"\u003e\n \u003cp\u003e1.70%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.584158415841586%\" colspan=\"2\" valign=\"bottom\" style=\"width: 26.4378%;\"\u003e\n \u003cp\u003eGrade 3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.062706270627064%\" colspan=\"2\" valign=\"bottom\" style=\"width: 9.0445%;\"\u003e\n \u003cp\u003e0/636\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.072607260726073%\" valign=\"bottom\" style=\"width: 6.4007%;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.584158415841586%\" colspan=\"2\" valign=\"bottom\" style=\"width: 26.4378%;\"\u003e\n \u003cp\u003eGrade 4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.062706270627064%\" colspan=\"2\" valign=\"bottom\" style=\"width: 9.0445%;\"\u003e\n \u003cp\u003e1/636\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.072607260726073%\" valign=\"bottom\" style=\"width: 6.4007%;\"\u003e\n \u003cp\u003e0.16%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.584158415841586%\" colspan=\"2\" valign=\"bottom\" style=\"width: 26.4378%;\"\u003e\n \u003cp\u003eGrade 5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"27.062706270627064%\" colspan=\"2\" valign=\"bottom\" style=\"width: 9.0445%;\"\u003e\n \u003cp\u003e0/636\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.072607260726073%\" valign=\"bottom\" style=\"width: 6.4007%;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"330\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"80.60606060606061%\" colspan=\"3\" valign=\"bottom\" style=\"width: 19.1338%;\"\u003e\n \u003cp\u003eTable 5 Infectious complications\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.393939393939394%\" valign=\"bottom\" style=\"width: 11.1425%;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"60.48632218844985%\" colspan=\"2\" style=\"width: 12.8139%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.589665653495441%\" style=\"width: 8.3569%;\"\u003e\n \u003cp\u003en/N\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.45288753799392%\" style=\"width: 11.1425%;\"\u003e\n \u003cp\u003e(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"65.95744680851064%\" colspan=\"2\" style=\"width: 16.5223%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eInfectious complications\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.589665653495441%\" style=\"width: 8.3569%;\"\u003e\n \u003cp\u003e7/636\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.45288753799392%\" style=\"width: 11.1425%;\"\u003e\n \u003cp\u003e1.10%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"100%\" colspan=\"4\" style=\"width: 36.0218%;\"\u003e\n \u003cp\u003eType of infectious complication\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"48.78787878787879%\" style=\"width: 28.0305%;\"\u003e\n \u003cp\u003eProstatitis \u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.575757575757574%\" colspan=\"2\" style=\"width: 10.0979%;\"\u003e\n \u003cp\u003e3/636\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.393939393939394%\" style=\"width: 11.1425%;\"\u003e\n \u003cp\u003e0.50%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"48.78787878787879%\" style=\"width: 28.0305%;\"\u003e\n \u003cp\u003eEpididymitis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.575757575757574%\" colspan=\"2\" style=\"width: 10.0979%;\"\u003e\n \u003cp\u003e1/636\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.393939393939394%\" style=\"width: 11.1425%;\"\u003e\n \u003cp\u003e0.16%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"48.78787878787879%\" style=\"width: 28.0305%;\"\u003e\n \u003cp\u003eInfection requiring hospitalization\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.575757575757574%\" colspan=\"2\" style=\"width: 10.0979%;\"\u003e\n \u003cp\u003e2/636\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.393939393939394%\" style=\"width: 11.1425%;\"\u003e\n \u003cp\u003e0.30%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"48.78787878787879%\" style=\"width: 28.0305%;\"\u003e\n \u003cp\u003eUrosepsis wit ICU\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.575757575757574%\" colspan=\"2\" style=\"width: 10.0979%;\"\u003e\n \u003cp\u003e1/636\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"19.393939393939394%\" style=\"width: 11.1425%;\"\u003e\n \u003cp\u003e0.16%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eWe could not determine any risk factors for infectious complications (age p=0.44, diabetes mellitus p=0.23, indwelling catheter p=0.26, number of cores p =0.6, prostate volume p=0.44), post-interventional bleeding (age p=0.75, under anticoagulant agent p=0.5, number of cores p =0.14, prostate volume p=0.10). Table 6 highlights those patients who suffered from an infectious complication and their clinical details (see table 6).\u003c/p\u003e\u003cp\u003e\u003cimg src=\"data:image/png;base64,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\" width=\"1076\" height=\"265\"\u003e\u003cbr\u003e\u003c/p\u003e"},{"header":"4. Discussion","content":"\u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003e4.1. Main Findings\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eOur study reported complications after transperineal prostate biopsy omitting peri-interventional antibiotic prophylaxis and not screening for bacteriuria in a single-center retrospective cohort of 632 patients.\u003c/p\u003e \u003cp\u003eMost trials do not mention if patients were excluded from the trial after performing urine analysis showing bacteriuria. In our cohort, patients were not systematically screened for underlying UTI/bacteriuria. As the transperineal route does not systematically injure the mucosa, there is no rationale for systematic bacteriuria screening. If there is clinical evidence of symptomatic UTI, we perform further diagnostics including urine microscopy and cultures, and biopsy is postponed after treatment of the underlying UTI.\u003c/p\u003e \u003cp\u003eFurthermore, we did not exclude patients with a \"high risk for infectious complication after prostate biopsy.\" In our cohort, the only contraindication for prostate biopsy would have been a clinically evident underlying UTI. If the patient complained of pollacisuria with alguria and/or fever, we would collect a urine sample, and if deemed necessary, start an antibiotic therapy. However, in our cohort of 650 patients, we did not postpone any prostate biopsy due to UTI. High risk for infectious complication after prostate biopsy is not clearly defined. In the NORAPP trial, the following criteria were defined for high risk: indwelling urinary catheter, immunodeficiencies, high risk of infective endocarditis, or a history of thromboembolic disease.\u003c/p\u003e \u003cp\u003eWe reported a low complication rate of 1.9% with 11 Clavien Dindo grade (CD) 2 complications and one CD 4 complication. The most common complications were infectious complications. The rate of infectious complications for the transperineal prostate biopsy without antibiotic prophylaxis in our cohort (ca. 1. %) seemed to be lower than for transrectal prostate biopsy with antibiotic prophylaxis (approx. 5%)[\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. The total number of low-grade complications may have been a little higher, as not all patients may have been referred back to our clinic and remember retrospectively if they have been prescribed an oral medication (i.e. antibiotics) by a private consultant. Higher-grade complications (Clavien Dindo Grade\u0026thinsp;\u0026gt;\u0026thinsp;2) were likely not missed, as our tertiary medical care center comprises the only urological unit in a radius of about 75 km. Risk factors for infectious or bleeding complications did not meet statistical significance. This may have been due to our cohort's relatively low number of complications.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003e4.2. Findings of biopsy results\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eHistologically confirmed prostate cancer was more often found in fusion biopsy than in systematic biopsies (Tables\u0026nbsp;2 and 3). High-grade prostate cancer (ISUP\u0026thinsp;\u0026gt;\u0026thinsp;3) was more frequently found in the group of systematic biopsies. An explanation could be that we did not perform upfront MRIs when there was a high risk for prostate cancer, such as PSA\u0026thinsp;\u0026gt;\u0026thinsp;20 ng/ml or suspicious DRE. Therefore, systematic biopsies had a negative selection bias for ISUP grade compared to the group of MRI fusion biopsies.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003e4.3. Limitations\u003c/h2\u003e \u003cp\u003e \u003cdiv class=\"BlockQuote\"\u003e \u003cp\u003eThe main limitation of this study is that follow-up data has been collected with a retrospective chart review. Also, as mentioned, our tertiary referral clinic is the only hospital with a urology department in a radius of around 75 km, but other urologist/physician may have treated minor adverse events such as UTI without fever or a simple postoperative prostatitis two staged and some patients might not have recalled correctly afterwards.\u003c/p\u003e \u003c/div\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"5. Conclusions","content":"\u003cp\u003eOur report confirmed existing data showing a low number of infectious complications when using the transperineal route for prostate biopsies and omitting antibiotic prophylaxis. We did not assess systematically for underlying bacteriuria and still had a very low complication rate. Omitting antibiotic prophylaxis and omitting screening for bacteriuria seems to be safe in transperineal prostate biopsies.\u003c/p\u003e "},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eAuthor Contributions:\u003c/strong\u003e Conceptualization, methods, and investigation, F.L.,T.S.; Data mining, investigation and draft preparation was incorporated in academic formulation for a medical doctor thesis at the University Medical Center of the Johannes Gutenberg-University Mainz; formal analysis, F.L.; writing\u0026mdash;original draft preparation, F.L.; writing\u0026mdash;review and editing, F.L.,T.S., A.N.; visualization, F.L..; conceptualization and supervision, A.N.. All authors have read and agreed to the published version of the manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding:\u003c/strong\u003e This research received no funding.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eInstitutional Review Board Statement:\u003c/strong\u003e This retrospective cohort study was conducted in accordance with the Declaration of Helsinki, and approved by our local ethics committee (Ethics Committee of the Mainz Medical Association (2022-16318)). Further, this study is reported in accordance with the STROBE statement guideline for cohort studies.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eInformed Consent Statement:\u0026nbsp;\u003c/strong\u003ePatient consent was waived due to the retrospective nature of this study. Further, given the provided information, patients cannot be identified (including by the patients themselves).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData Availability Statement:\u003c/strong\u003e De-identified data is available upon request from the authors.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgments:\u003c/strong\u003e None.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConflicts of Interest:\u003c/strong\u003e\u0026nbsp; All authors declare no conflict of interest.\u003c/p\u003e\n\u003cp dir=\"LTR\"\u003e\u003cstrong\u003eDisclaimer/Publisher\u0026rsquo;s Note:\u003c/strong\u003e The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of World Journal of Urology and/or the editor(s). World Journal of Urology and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eBasourakos SP, Alshak MN, Lewicki PJ, Cheng E, Tzeng M, DeRosa AP, Allaway MJ, Ross AE, Schaeffer EM, Patel HD, Hu JC, Gorin MA (2022) Role of Prophylactic Antibiotics in Transperineal Prostate Biopsy: A Systematic Review and Meta-analysis. Eur Urol Open Sci 37:53\u0026ndash;63. doi: 10.1016/j.euros.2022.01.001\u003c/li\u003e\n\u003cli\u003eBell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M (2014) A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis 14:1\u0026ndash;25. doi: 10.1186/1471-2334-14-13\u003c/li\u003e\n\u003cli\u003eBootsma AMJ, Laguna Pes MP, Geerlings SE, Goossens A (2008) Antibiotic Prophylaxis in Urologic Procedures: A Systematic Review. Eur Urol 54:1270\u0026ndash;1286. doi: 10.1016/j.eururo.2008.03.033\u003c/li\u003e\n\u003cli\u003eCastellani D, Pirola GM, Law YXT, Gubbiotti M, Giulioni C, Scarcella S, Wroclawski ML, Chan E, Chiu PKF, Teoh JYC, Gauhar V, Rubilotta E (2022) Infection Rate after Transperineal Prostate Biopsy with and without Prophylactic Antibiotics: Results from a Systematic Review and Meta-Analysis of Comparative Studies. Journal of Urology 207:25\u0026ndash;34\u003c/li\u003e\n\u003cli\u003eDing X fei, Luan Y, Lu S ming, Zhou G chen, Huang T bao, Zhu L yong, Guo C hao (2021) Risk factors for infection complications after transrectal ultrasound-guided transperineal prostate biopsy. World J Urol 39:2463\u0026ndash;2467. doi: 10.1007/s00345-020-03454-y\u003c/li\u003e\n\u003cli\u003eGuo LH, Wu R, Xu HX, Xu JM, Wu J, Wang S, Bo XW, Liu BJ (2015) Comparison between Ultrasound Guided Transperineal and Transrectal Prostate Biopsy: A Prospective, Randomized, and Controlled Trial. Sci Rep 5:1\u0026ndash;10. doi: 10.1038/srep16089\u003c/li\u003e\n\u003cli\u003eHulscher ME, Grol RP, van der Meer JW (2010) Antibiotic prescribing in hospitals: a social and behavioural scientific approach. Lancet Infect Dis 10:167\u0026ndash;175. doi: 10.1016/S1473-3099(10)70027-X\u003c/li\u003e\n\u003cli\u003eJacewicz M, G\u0026uuml;nzel K, Rud E, Sandb\u0026aelig;k G, Magheli A, Busch J, Hinz S, Baco E (2022) Antibiotic prophylaxis versus no antibiotic prophylaxis in transperineal prostate biopsies (NORAPP): a randomised, open-label, non-inferiority trial. Lancet Infect Dis 22:1465\u0026ndash;1471. doi: 10.1016/S1473-3099(22)00373-5\u003c/li\u003e\n\u003cli\u003eKohl T, Sigle A, Kuru T, Salem J, Rolfs H, Kowalke T, Suarez-Ibarrola R, Michaelis J, Binder N, Jilg CA, Miernik A, Grabbert MT, Schultze-Seemann W, Gratzke C, Porres D (2021) Comprehensive analysis of complications after transperineal prostate biopsy without antibiotic prophylaxis: results of a multicenter trial with 30 days\u0026rsquo; follow-up. Prostate Cancer Prostatic Dis 1\u0026ndash;5. doi: 10.1038/s41391-021-00423-3\u003c/li\u003e\n\u003cli\u003eMottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, van der Kwast TH, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, van der Poel HG, Rouvi\u0026egrave;re O, Schoots IG, Tilki D, Wiegel T, Willemse PPM, Cornford P (2021) EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer\u0026mdash;2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 79:243\u0026ndash;262. doi: 10.1016/j.eururo.2020.09.042\u003c/li\u003e\n\u003cli\u003ePepdjonovic L, Tan GH, Huang S, Mann S, Frydenberg M, Moon D, Hanegbi U, Landau A, Snow R, Grummet J (2017) Zero hospital admissions for infection after 577 transperineal prostate biopsies using single-dose cephazolin prophylaxis. World J Urol 35:1199\u0026ndash;1203. doi: 10.1007/s00345-016-1985-1\u003c/li\u003e\n\u003cli\u003eSigle A, Suarez-Ibarrola R, Pudimat M, Michaelis J, Jilg CA, Miernik A, Grabbert MT, Schultze-Seemann W, Gratzke C, Schlager D (2021) Safety and side effects of transperineal prostate biopsy without antibiotic prophylaxis. Urologic Oncology: Seminars and Original Investigations 39:782.e1-782.e5. doi: 10.1016/j.urolonc.2021.02.016\u003c/li\u003e\n\u003cli\u003eSigle A, Suarez-Ibarrola R, Pudimat M, Michaelis J, Jilg CA, Miernik A, Grabbert MT, Schultze-Seemann W, Gratzke C, Schlager D, Pepdjonovic L, Tan GH, Huang S, Mann S, Frydenberg M, Moon D, Hanegbi U, Landau A, Snow R, Grummet J, Baba K, Sekine Y, Miyazawa Y, Syuto T, Nomura M, Koike H, Matsui H, Shibata Y, Ito K, Suzuki K (2017) Safety and side effects of transperineal prostate biopsy without antibiotic prophylaxis. World J Urol 39:1199\u0026ndash;1203. doi: 10.1007/s00345-016-1985-1\u003c/li\u003e\n\u003cli\u003eXiang J, Yan H, Li J, Wang X, Chen H, Zheng X (2019) Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: A systematic review and meta-analysis. World J Surg Oncol 17:1\u0026ndash;11. doi: 10.1186/s12957-019-1573-0\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"world-journal-of-urology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"wjur","sideBox":"Learn more about [World Journal of Urology](https://link.springer.com/journal/345)","snPcode":"345","submissionUrl":"https://submission.nature.com/new-submission/345/3","title":"World Journal of Urology","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"Prostatic Neoplasms [MeSH], Image-Guided Biopsy [MeSH], Transperineal, Transrectal, Fusion biopsy, Intraoperative complications [MeSH]","lastPublishedDoi":"10.21203/rs.3.rs-4875283/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4875283/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003ePurpose\u003c/h2\u003e \u003cp\u003eThe pursuit of effective and safe early detection methods for prostate cancer has led to advancements in non-invasive tools, yet the annual performance of one million prostate biopsies in the EU underscores the challenges. The transperineal approach, recommended by the EAU, offers reduced infectious complications compared to transrectal biopsies. The role of antibiotic prophylaxis in transperineal biopsies remains ambiguous, necessitating investigation due to concerns about antibiotic resistance and the impact on public health.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eThis retrospective study analyzed 636 patients who underwent transperineal prostate biopsies between January 2019 and August 2020. The primary endpoint was postinterventional infectious complications, with secondary endpoints including the general complication rate and associated risk factors.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eAmong the cohort (median age 68), 12 complications were recorded, yielding a 1.9% complication rate. Infectious complications requiring hospitalization and antibiotic treatment occurred in 1.1% of cases. No identified risk factors were associated with infectious complications or post-interventional bleeding. Complications included gross hematuria, urinary retention requiring catheterization, and one case necessitating intensive care. Notably, the cohort did not systematically screen for bacteriuria, and patients with high risk for complications were not excluded. The complication rate appeared lower than reported for transrectal biopsies with antibiotic prophylaxis.\u003c/p\u003e\u003ch2\u003eConclusion\u003c/h2\u003e \u003cp\u003eThis study supports the safety of omitting antibiotic prophylaxis in transperineal prostate biopsies, showcasing a minimal infectious complication rate. The findings contribute to the ongoing discourse on antibiotic stewardship, emphasizing the need for judicious use to mitigate resistance.\u003c/p\u003e","manuscriptTitle":"Retrospective, single center evaluation of perineal prostate biopsy omitting antibiotic prophylaxis and omitting periinterventional screening for bacteriuria","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-10-15 08:18:34","doi":"10.21203/rs.3.rs-4875283/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2024-12-19T05:01:36+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-12-18T16:07:08+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"92985078978317946676800774131757958771","date":"2024-12-04T13:24:18+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"160824219035877708216933057394978424533","date":"2024-12-02T14:28:47+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-09-12T05:05:00+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"199033766471439781918451740258155859349","date":"2024-08-30T06:35:14+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2024-08-27T14:46:59+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2024-08-21T04:02:07+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2024-08-20T13:33:50+00:00","index":"","fulltext":""},{"type":"submitted","content":"World Journal of Urology","date":"2024-08-07T13:55:33+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"world-journal-of-urology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"wjur","sideBox":"Learn more about [World Journal of Urology](https://link.springer.com/journal/345)","snPcode":"345","submissionUrl":"https://submission.nature.com/new-submission/345/3","title":"World Journal of Urology","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"7c707908-6307-4db0-a990-8056173b1fa6","owner":[],"postedDate":"October 15th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2025-06-23T16:05:14+00:00","versionOfRecord":{"articleIdentity":"rs-4875283","link":"https://doi.org/10.1007/s00345-025-05672-8","journal":{"identity":"world-journal-of-urology","isVorOnly":false,"title":"World Journal of Urology"},"publishedOn":"2025-06-19 15:57:09","publishedOnDateReadable":"June 19th, 2025"},"versionCreatedAt":"2024-10-15 08:18:34","video":"","vorDoi":"10.1007/s00345-025-05672-8","vorDoiUrl":"https://doi.org/10.1007/s00345-025-05672-8","workflowStages":[]},"version":"v1","identity":"rs-4875283","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4875283","identity":"rs-4875283","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}